U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H11ClO3
Molecular Weight 226.656
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALCLOFENAC

SMILES

OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1

InChI

InChIKey=ARHWPKZXBHOEEE-UHFFFAOYSA-N
InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/26888 https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox-2-inhibitors

Alclofenac (Preservex) is a non-steroidal anti-inflammatory agent advocated for use in rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis. Aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites which include diclofenac and 4’-hydroxy diclofenac. Skin rash is the most frequent side-effect, which in a small proportion of affected patients may be associated with systemic effects. A cutaneous reaction appears to be more likely in patients with a history of previous allergy to penicillin and other drugs. In June 2013 was told about the new contraindications and warnings for diclofenac. This was after a review by European regulators concluded that the risk of arterial thrombotic events (myocardial infarction; stroke) with diclofenac is greater than with other non-selective NSAIDs and similar to the COX-2 inhibitors.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PRINALGIN

Approved Use

Unknown
Primary
PRINALGIN

Approved Use

Unknown
Primary
PRINALGIN

Approved Use

Unknown
Primary
PRINALGIN

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
1975
Renal papillary necrosis after aspirin and alclofenac.
1977 Dec 10
Percutaneous permeation enhancement by terpenes: mechanistic view.
2008
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
2009 Sep
Patents

Sample Use Guides

The recommended dose is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening
Route of Administration: Oral
In Vitro Use Guide
Alclofenac showed no mutagenic, transforming or clastogenic potential in any in vitro experiment.
Name Type Language
ALCLOFENAC
INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
ALCLOPHENAC
Common Name English
PRINALGIN
Brand Name English
ALCLOFENAC [MI]
Common Name English
ALCLOFENAC [USAN]
Common Name English
MERVAN
Brand Name English
ALLOPYDIN
Brand Name English
MEDIFENAC
Brand Name English
BENZENEACETIC ACID, 3-CHLORO-4-(2-PROPEN-1-YLOXY)-
Systematic Name English
NEOSTON
Brand Name English
BENZENEACETIC ACID, 3-CHLORO-4-(2-PROPENYLOXY)-
Common Name English
W-7320
Code English
ZUMARIL
Brand Name English
alclofenac [INN]
Common Name English
MY-101
Code English
EPINAL
Brand Name English
ALCLOFENAC [MART.]
Common Name English
Alclofenac [WHO-DD]
Common Name English
ALCLOFENAC [JAN]
Common Name English
[4-(Allyloxy)-3-chlorophenyl]acetic acid
Systematic Name English
W 7320
Code English
REUFENAC
Brand Name English
NEOSTEN
Brand Name English
Classification Tree Code System Code
WHO-VATC QM01AB06
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
WHO-ATC M01AB06
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
Code System Code Type Description
CHEBI
31183
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
PUBCHEM
30951
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
MERCK INDEX
m1004
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
107
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
NCI_THESAURUS
C174701
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
SMS_ID
100000087734
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
INN
2826
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
ECHA (EC/EINECS)
244-795-4
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
EPA CompTox
DTXSID4020038
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
ChEMBL
CHEMBL94081
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
DRUG BANK
DB13167
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
FDA UNII
M9CP5H21N8
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
CAS
22131-79-9
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
EVMPD
SUB05299MIG
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY
WIKIPEDIA
ALCLOFENAC
Created by admin on Sat Dec 16 17:52:22 UTC 2023 , Edited by admin on Sat Dec 16 17:52:22 UTC 2023
PRIMARY